Steris Plc (STE) Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025 (Q2 of Fiscal Year 2026). Steris Plc is a global provider of products and services supporting patient care, with a focus on infection prevention. The company operates through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in May 2024 and is reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $1,460.3 million | $1,328.9 million | $2,851.4 million | $2,608.4 million |
| Gross Profit | $645.9 million | $578.8 million | $1,273.9 million | $1,151.2 million |
| Gross Margin | 44.2% | 43.6% | 44.7% | 44.1% |
| Income from Operations | $265.8 million | $219.7 million | $511.8 million | $405.2 million |
| Net Income (Attributable to Shareholders) | $191.9 million | $150.0 million | $369.2 million | $295.4 million |
| Diluted EPS | $1.94 | $1.51 | $3.74 | $2.98 |
| Operating Cash Flow (YTD) | $707.8 million (vs. $554.5 million YTD 2025) | |||
| Free Cash Flow (YTD) | $527.7 million (vs. $344.5 million YTD 2025) | |||
| Total Debt | $1,897.3 million (as of Sept 30, 2025) | |||
| Cash and Equivalents | $319.2 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9.9% in Q2 and 9.3% YTD, driven by organic growth across all segments due to higher volume and pricing. Service revenues grew 12.9% (Q2) and 12.7% (YTD).
- Margin Expansion: Gross margins improved by 60 basis points YTD (44.7% vs. 44.1%), aided by pricing, productivity, and mix, partially offset by inflation and tariff costs.
- Restructuring Impact: Restructuring expenses decreased significantly to $3.9 million YTD 2026 compared to $28.5 million YTD 2025, contributing to higher operating income.
- Debt Reduction: Total debt decreased to $1.90 billion from $2.04 billion at the prior fiscal year-end, following the repayment of $125.0 million in Private Placement Senior Notes.
- Segment Performance:
- Healthcare: Revenue up 9.5% (Q2); Operating income up 13.8%.
- AST: Revenue up 9.7% (Q2); Operating income up 16.1%.
- Life Sciences: Revenue up 13.3% (Q2); Operating income up 11.5%.
Guidance, Outlook, and Risks
Management Commentary: Management attributes growth to volume and pricing benefits. The company expects restructuring costs to be insignificant for the remainder of Fiscal 2026. Backlog for the Healthcare segment stands at $427.5 million, and Life Sciences backlog is $113.7 million.
Capital Allocation: The company repurchased $100.0 million of shares in the first six months of Fiscal 2026. $200.0 million remains available under the current share repurchase program. Cash dividends declared were $1.20 per share YTD.
Risks and Contingencies:
- Legal Proceedings: The company has entered into settlement agreements regarding ethylene oxide (EO) litigation in Illinois, with a liability of up to $48.2 million recorded. The claims administration process is expected to continue through the first half of Fiscal 2027.
- Tax Matters: The company is contesting IRS Notices of Deficiency regarding a deemed dividend inclusion, which could result in a cumulative tax liability of approximately $50.0 million. No reserve has been established.
- Market Risks: Exposure to foreign currency fluctuations, commodity prices (nickel), and inflation/tariff costs impacting margins.
Investor Verification Checklist
- EO Litigation Settlement: Verify the status of the Illinois ethylene oxide claims administration and potential for additional costs beyond the $48.2 million accrual.
- IRS Dispute: Monitor the outcome of the U.S. Tax Court petitions regarding the $50.0 million potential tax liability.
- Margin Sustainability: Assess the ability to maintain gross margin expansion given ongoing inflation and tariff headwinds.
- Backlog Conversion: Track the conversion rate of the $541.2 million combined backlog (Healthcare and Life Sciences) into future revenue.
- Debt Profile: Confirm the interest rate environment impact on the $1.9 billion debt load and the utilization of the $1.1 billion revolving credit facility.